
Sep 15
11/10/2020
The Clinical Content & Reuse (CC&R) initiative aims to enhance clinical trial processes by providing harmonized structure and proposed model content within clinical trial documents (e.g., Common Protocol Template, Statistical Analysis Plan, and Clinical Study Report) that can be reused throughout the project lifecycle to enable digitization and traceability through automation. The initiative’s guiding principles include a streamlined and consistent structure and content that can be used across multiple documents and processes, and is aligned with Good Clinical Practice (GCP), ICH and EU requirements, with elements drawn from Clarity and Openness in Reporting (CORE) Reference.
Our annual release continues to provide benefits to regulators, investigator sites, patients, and research sponsors.
This year, the team is also excited to present an updated graphic that illustrates the interconnectedness, continued growth and development of the CC&R Initiative. Presented as three interconnected triangles, the image denotes the close relationships among the clinical template suite, harmonized model content and reuse capabilities. The initiative is grounded by its guiding principles and flexible implementation options.
Looking ahead, the team anticipates a busy 2021 as they will continue to make content enhancements, including enhancing eTemplates to minimize adoption barriers. They are also assessing adoption of new automation technologies, including a clinical trial registration tool and a ClinicalTrials.gov export profile.
We welcome you to visit our updated CC&R initiative website and solutions page to learn more and we invite you to share your feedback on the Clinical Template Suite.
By Mark Makurath, Head of GCD Standards & Training Excellence at Merck
TransCelerate is thrilled to announce the launch of the Digital Data Flow Initiative’s Study Definition Repository Reference Implementation (SDR RI) Minimal Viable Product (MVP). The SDR RI is a model implementation of a repository that uses a Unified Study Definitions Model to facilitate data exchange. The source code and configurations are available by means of…
In a new LinkedIn article, Janice Chang, CEO of TransCelerate, and Nicholas Brooke, CEO of The Synergist & PFMD, outline how efforts like the Clinical Trial Data Network, supported by TransCelerate through technical expertise and industry-vetted solutions from our Digital Data Flow initiative, aim to make clinical trial information more structured, connected, and accessible across…
Artificial Intelligence (AI) is reasonably well established in discovery and preclinical research, with success in areas such as target identification and molecular modeling. However, in clinical development, adoption has been fragmented and challenging to embed across the lifecycle. Read the full article by Rob DiCicco from Drug Discovery News here.